An asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet
Journal
Diabetes Care
Journal Volume
21
Journal Issue
7
Pages
1058-1061
Date Issued
1998
Author(s)
Abstract
OBJECTIVE- To assess the efficacy, safety, and tolerability of acarbose versus placebo during a 24-week treatment period in Asian type 2 diabetic patients with dietary failure. RESEARCH DESIGN AND METHODS- After a 6-week screening period, 126 multiethnic Asian type 2 diabetic patients (64 men, 62 women; mean age ± SD, 53.4 ± 10 years) were randomized to receive acarbose (n = 63) or placebo (n = 63). The dosage was increased from 50 mg t.i.d. at week 0 to 100 mg t.i.d. at week 4. Patients were then followed up at weeks 10, 16, and 24. At each visit, body weight, blood pressure, and metabolic indexes were measured. At weeks 0 and 24, fasting plasma glucose and insulin were measured before and 1 h after the administration of an individually tailored breakfast. RESULTS- Using the intention-to-treat analysis, there were greater reductions in (mean [95% CI]) HbA(1c) (-0.70 [-1.00 to -0.39] vs. -0.27% [-0.54 to 0];P = 0.04), fasting plasma glucose (-0.37 [-0.75 to 0.02] vs. 0.41 mmol/l [-0.08 to 0.90]; P = 0.017) and 1-h plasma glucose (- 0.77 [-1.44 to -0.10] vs. 0.65 mmol/l [-0.07 to 1.36]; P = 0.05) in the acarbose group compared with the placebo group. With acarbose treatment, 78% of patients achieved an HbA(1c) <8% compared with 56% in the placebo group (P = 0.003). There was a greater reduction in body weight (-1.31 [-2.46 to - 0.15] vs. 0.16 kg [-3.36 to 0.10]; P = 0.02) and higher incidence of flatulence (56 vs. 37%; P = 0.032) in the acarbose than in the placebo group. Using baseline HbA(1c) and race as covariates, there were no significant inter-ethnic differences in treatment responses (P = 0.232 for treatment- race interaction; P < 0.001 for treatment effect). The dropout rates were similar between the two groups (acarbose, 11 of 63; placebo, 6 of 63). There were no significant laboratory adverse events in either group. CONCLUSIONS- In this multicenter study involving six ethnic groups, acarbose 100 mg t.i.d. was an effective, safe, and generally well-tolerated therapy in Asian type 2 diabetic patients with dietary failure. In some patients with troublesome gastrointestinal symptoms, a lower dosage may be necessary.
SDGs
Other Subjects
acarbose; glibenclamide; metformin; sulfonylurea; abdominal distension; adult; article; Asian; clinical trial; controlled clinical trial; controlled study; diabetic diet; diarrhea; drug efficacy; drug safety; drug tolerability; female; flatulence; human; major clinical study; male; multicenter study; non insulin dependent diabetes mellitus; randomized controlled trial; treatment indication; treatment outcome
Publisher
American Diabetes Association Inc.
Type
journal article